A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
In this study, participants with MSI-H or dMMR advanced colorectal carcinoma will be
randomly assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6
standard of care (SOC) chemotherapy regimens for the treatment of advanced colorectal
carcinoma. The primary study hypothesis is that pembrolizumab will prolong progression-free
survival (PFS) compared to current SOC chemotherapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society